Rotavirus vaccine - Bio-Farma/Murdoch-Childrens-Research-Institute
Alternative Names: RV3 BB; RV3 BB vaccine - Bio Farma/Murdoch Childrens Research Institute; RV3-BB - Bio-Farma/Murdoch-Childrens-Research-Institute; RV3-BB vaccineLatest Information Update: 04 Dec 2023
At a glance
- Originator Murdoch Childrens Research Institute
- Developer Bio Farma Indonesia; Murdoch Childrens Research Institute; PATH
- Class Attenuated vaccines; Rotavirus vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Rotavirus infections
Most Recent Events
- 30 May 2023 PT Bio Farma completes a phase-III clinical trials in Rotavirus infections (In neonates) in Indonesia (PO) (NCT04185545)
- 09 Sep 2022 PATH and SK Bioscience completes a phase II trial for Rotavirus infections (In neonates, In infants, Prevention) in South Africa (IM) (NCT04344054)
- 28 May 2021 No recent reports of development identified for phase-I development in Rotavirus-infections(In adolescents, In children, In infants, In neonates, Prevention, In adults) in Indonesia (PO, Drops)